1. Trial completion, EU approved,IL-6 reduced by 49.1%
    mike demunbrun mike demunbrun United States says:
    July 7, 2011 at 11:03 AM

    Cytosorbents Corp. CTSO, NJ based,has been awarded EU approval for their cytosorb filter (a hemoperfusion technology utilizing their proprietary hydrophobic polymer beads {filter}.)which reduce inflamatory mediators [IL 6 & other cytokines]thus allowing the previously "over active" immune system to fight infection in severe sepsis, as well as other recently discovered indications.

    STATE OF THE ART DIALYSIS TECHNOLOGY DOES NOT REMOVE HARMFUL EXCESSIVE CYTOKINES

    Cytosorbents cytosorb was successful in removeing 49.1% of IL-6 during recently completed trials (EU approval was awarded prior to trial completion). Product will be released for field application this fall in Europe. Discussions with the FDA will begin soon.

    Reply
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback